Linked Life Data

20339966

Source:http://linkedlifedata.com/resource/pubmed/id/20339966

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-3-26
pubmed:abstractText
Acute coronary syndrome (ACS) is a clinical syndrome caused by acute myocardial ischemia and a severe stage of coronary atherosclerosis heart disease. The aim of this study was to clarify whether ramipril was a therapeutic agent against monocyte chemoattractant protein 1 (MCP-1), interleukin 18 (IL-18), and interleukin 10 (IL-10) in elderly patients with ACS. A total of 190 subjects including 72 elderly patients with ACS (78.1% male, mean age 67.12 +/- 5.06 years), 60 elderly patients with stable angina pectoris (76.9% male, mean age 68.00 +/- 4.52 years), and 58 healthy volunteers (77.8% male, mean age 65.96 +/- 4.18 years) were recruited into the study. Serum MCP-1, IL-10, and IL-18 were determined in 132 elderly patients by enzyme-linked immunosorbent assay (ELISA) before and after treatment with low doses of ramipril (2.5-5 mg/day), and were determined in 58 healthy volunteers. The levels of serum MCP-1 and IL-18 were much higher in elderly patients with ACS than those in elderly patients with SAP and healthy volunteers. After treating with ramipril, the levels of MCP-1 and IL-18 were decreased in elderly patients with ACS. Moreover, ramipril significantly increased serum IL-10 in elderly patients with ACS. Ramipril plays an important role in elderly patients with ACS. With decreasing MCP-1 and IL-18, it can ameliorate cytokine-associated cardiac damage. This study may provide a new recognition of angiotensin-converting enzyme inhibitor for the treatment of ACS.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1615-2573
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
77-81
pubmed:meshHeading
pubmed-meshheading:20339966-Acute Coronary Syndrome, pubmed-meshheading:20339966-Age Factors, pubmed-meshheading:20339966-Aged, pubmed-meshheading:20339966-Angina Pectoris, pubmed-meshheading:20339966-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:20339966-Anti-Inflammatory Agents, pubmed-meshheading:20339966-Biological Markers, pubmed-meshheading:20339966-Chemokine CCL2, pubmed-meshheading:20339966-China, pubmed-meshheading:20339966-Cross-Sectional Studies, pubmed-meshheading:20339966-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:20339966-Female, pubmed-meshheading:20339966-Humans, pubmed-meshheading:20339966-Inflammation Mediators, pubmed-meshheading:20339966-Interleukin-10, pubmed-meshheading:20339966-Interleukin-18, pubmed-meshheading:20339966-Male, pubmed-meshheading:20339966-Middle Aged, pubmed-meshheading:20339966-Ramipril, pubmed-meshheading:20339966-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.
pubmed:affiliation
Department of Geriatrics, Qi-Lu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, PR China.
pubmed:publicationType
Journal Article, Randomized Controlled Trial